Effects of ARA 290 on neuropathic pain in patients with type 1 diabetes mellitus

Trial Profile

Effects of ARA 290 on neuropathic pain in patients with type 1 diabetes mellitus

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Cibinetide (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Type 1 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2016 According to an Araim Pharmaceuticals media release, this study is on schedule and results expected later in the year 2016.
    • 05 Jan 2015 New trial record
    • 15 Dec 2014 This proof-of-concept trial will be initiated in 2015, according to a North Shore-Long Island Jewish Health System media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top